Ori Biotech in a $100m in Series B funding round led by Novalis LifeSciences

Ori Biotech, a London, UK and Jersey, USA-based biotech company, announced raising $100 million series B round.

The money was raised from investors led by Novalis LifeSciences, joined by Puhua Capital and Chimera Abu Dhabi and existing investors Amadeus Capital Partners, Delin Ventures, Northpond Ventures and Octopus Ventures.

The proceeds will be used to further expand key personnel across all functions, in order to transition through pre-commercialization to the launch of its innovative CGT manufacturing platform. It is also launching its Lightspeed Early Access Program (LEAP), allowing select partners to gain pre-launch access to the platform in 2022.

Ori Biotech, founded in2015 by Dr. Farlan Veraitch and Professor Chris Mason. and led by CEO Jason C. Foster, developed a proprietary, flexible manufacturing platform that closes, automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of life-saving treatments.

Ori Biotech previously raised $30 million series A from a syndicate led by Northpond Ventures in 2020.